

# Children's Hospital and Health System Chorus Community Health Plans (CCHP) Policy and Procedure

This policy applies to the following entity(s):

- |  |   |
|--|---|
| <input type="checkbox"/> CHW – Milwaukee                         | <input type="checkbox"/> CHW - Fox Valley                         |
| <input type="checkbox"/> CHHS Foundation                         | <input type="checkbox"/> CHW - Surgicenter                        |
| <input type="checkbox"/> CHW – Community Services Division       | <input checked="" type="checkbox"/> Chorus Community Health Plans |
| <input type="checkbox"/> Children's Medical Group - Primary Care | <input type="checkbox"/> Children's Specialty Group               |
| <input type="checkbox"/> Children's Medical Group - Urgent Care  | <input type="checkbox"/> CHHS Corporate Departments               |

## Medical Utilization Management Policy

**SUBJECT: SIGNATERA AND STRATANGS**

### **INCLUDED PRODUCT(S):**

#### **Medicaid**

BadgerCare Plus

Care4Kids Program

#### **Individual and Family**

Commercial

Marketplace

### **PURPOSE OR DESCRIPTION:**

The purpose of this policy is to define criteria for medically necessary use of the Signatera circulating tumor deoxyribonucleic acid (DNA) blood test and the Strata Next Generation Sequencing (NGS) tissue sample test.

#### **Definitions:**

Signatera is a molecular residual disease (MRD) assay using circulating tumor deoxyribonucleic acid (ctDNA) to help identify early cancer relapse.

StrataNGS is a gene tumor profiling test, which is performed on tissue sampling from solid organ tumors.

### **POLICY:**

Signatera or StrataNGS testing is considered medically necessary when ordered by an oncologist for patients diagnosed with the following:

1. Colon cancer

Effective: 6/23

Last reviewed: 10/23

Q:\CCHP Leadership\Utilization Management Medical Policies\APPROVED MEDICAL UM POLICIES

Developed by: CCHP Medical Directors

## 2. Rectal cancer

For all other uses, CCHP considers Signatera and StrataNGS NOT medically necessary.

### **REFERENCES**

1. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. *Nat Med*. Published online January 16, 2023. doi:10.1038/s41591-022-02115-4.
2. Reinert T, Henriksen T, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. *JAMA Oncol*. 2019;5(8):1124-1131.
3. Taniguchi H, Nakamura Y, Kotani D, et al. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. *Cancer Sci*. 2021;112(7):2915-2920.
4. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer. *JAMA Oncol*. 2019;5(12):1710-1717.
5. Vogel J, Felder S, Bhamra A, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. *Diseases of the Colon and Rectum*. 2022;65(2):148-177.
6. [www.natera.com](http://www.natera.com)
7. [www.strataoncology.com/stratangs](http://www.strataoncology.com/stratangs)